Current and future directions for Phase II trials in high-grade glioma (Q38094808)

28 August 2017

title

Current and future directions for Phase II trials in high-grade glioma (English)

1 reference

28 August 2017

main subject

phase II clinical trial

0 references

3

David A Reardon

1 reference

28 August 2017

4

Patrick Y Wen

1 reference

28 August 2017

2

Eudocia Q Lee

1 reference

28 August 2017

Brian M Alexander

1

1 reference

28 August 2017

language of work or name

1 reference

1 April 2013

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

28 August 2017

published in

1 reference

28 August 2017

volume

13

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

369-387

1 reference

Malignant gliomas in adults

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Current clinical development of PI3K pathway inhibitors in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Pathway inhibition: emerging molecular targets for treating glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

The BATTLE trial: personalizing therapy for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Bayesian adaptive randomized trial design for patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Antiangiogenic therapies for high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Angiogenesis in brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Safety of anticoagulation use and bevacizumab in patients with glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Brain tumor imaging in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Response criteria for glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

CXCR4 expression mediates glioma cell invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Integrins in cancer: biological implications and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

CNS immune privilege: hiding in plain sight

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

EGFRvIII-targeted vaccination therapy of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Mechanisms of immunomodulation in human glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Glioblastoma-derived mechanisms of systemic immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Immune defects observed in patients with primary malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Cancer stem cells in radiation resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Brain cancer propagating cells: biology, genetics and targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Contribution of Notch signaling activation to human glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Notch signaling enhances nestin expression in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Mitochondrial DNA integrity is essential for mitochondrial maturation during differentiation of neural stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

THE METABOLISM OF TUMORS IN THE BODY

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Understanding the Warburg effect: the metabolic requirements of cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Role of isocitrate dehydrogenase in glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

IDH mutation impairs histone demethylation and results in a block to cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

IDH mutations in glioma and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Antitumor effects of 2-oxoglutarate through inhibition of angiogenesis in a murine tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Metabolic modulation of glioblastoma with dichloroacetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Genetic instabilities in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Genome maintenance mechanisms for preventing cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

MGMT: its role in cancer aetiology and cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Targeted modulation of MGMT: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

A quantitative overview of radiosensitivity of human tumor cells across histological type and TP53 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Genotype-dependent radiosensitivity: clonogenic survival, apoptosis and cell-cycle redistribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Human tumor cells segregate into radiosensitivity groups that associate with ATM and TP53 status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Use of trans sodium crocetinate for sensitizing glioblastoma multiforme to radiation: laboratory investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

DNA repair targeting and radiotherapy: a focus on the therapeutic ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: rationale and strategies for radiosensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Inhibition of histone deacetylation: a strategy for tumor radiosensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Transforming fusions of FGFR and TACC genes in human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Blood-brain barrier: recent developments and clinical correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Genetically engineered T cells to target EGFRvIII expressing glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

Mismatch correction at O 6 -methylguanine residues in E. coli DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.158

21 January 2018

Identifiers

DOI

10.1586/ERN.12.158

1 reference

28 August 2017

1 reference